Merck: trial fails in colorectal cancer drug

(CercleFinance.com) - Merck reports the failure of its phase III KEYFORM-007 trial evaluating the investigational fixed-dose combination of favezelimab and Keytruda, for the treatment of previously treated PD-L1 positive metastatic microsatellite stable (MSS) colorectal cancer.


In the final pre-specified analysis, the combination failed to meet its primary objective of demonstrating an improvement in overall survival, compared with standard therapy (regorafenib or TAS-102).

The safety profile of the combination was consistent with that observed for its two components in previously reported studies, and no new safety signals were observed.


Copyright (c) 2024 CercleFinance.com. All rights reserved.